Aligos Therapeutics, Inc. 8-K

What Happened
Aligos Therapeutics (ALGS) announced on April 16, 2026 that it entered a License Agreement with Xiamen Amoytop Biotech Co., Ltd. granting Amoytop an exclusive, royalty‑bearing license to develop, manufacture and commercialize pevifoscorvir sodium for treatment/prevention/palliation of Hepatitis B (and HBV/HDV co‑infection) in mainland China, Taiwan, Hong Kong and Macau. The deal includes a $25 million upfront cash payment, potential development/regulatory/commercial milestone payments up to $420 million, and tiered high single‑digit royalties on net sales in the territory. The agreement is conditioned on Amoytop shareholder approval (expected within ~30 days) and will automatically terminate if approval is not received within 45 days of signing.

Key Details

• Effective date: April 16, 2026 (subject to Amoytop shareholder approval); automatic termination if approval not received within 45 days.
• Payments: $25M upfront; up to $420M in future milestones; tiered high single‑digit royalties on net sales.
• Territory & scope: Exclusive rights for pevifoscorvir sodium in mainland China, Taiwan, Hong Kong and Macau; Aligos retains rights to develop/manufacture/use the product outside the Territory or for uses outside the agreed Field.
• Responsibilities & IP: Amoytop will fund development, regulatory, manufacturing and commercialization in the Territory; Amoytop owns certain operational improvements but grants Aligos a perpetual, royalty‑free license to use those improvements outside the Territory. Data sharing and joint steering/development committees are required; technical transfer to Amoytop at Amoytop’s cost.
• Royalty duration: Royalties for each region continue until the later of (i) 10 years after first commercial sale in that region, (ii) expiration of patents claiming the product there, or (iii) loss of regulatory exclusivity.
• Other: License is subject to reservation of certain rights held by Aligos’s licensor (Emory University) and the terms of Aligos’s existing Emory license.

Why It Matters
This agreement monetizes Aligos’s pevifoscorvir program in Greater China, providing immediate non‑dilutive cash ($25M) and potential upside through milestones and royalties (up to $420M + royalties) while shifting development, regulatory and commercialization costs and risks in the Territory to Amoytop. Aligos preserves rights to exploit the asset outside the Territory and retains certain uses inside the Territory outside the licensed Field. The deal’s benefits are contingent on Amoytop shareholder approval and on Amoytop achieving regulatory and commercial milestones in the region, so investors should note the conditional nature of the transaction and the usual regulatory and execution risks.